Open AccessEngineered Small Extracellular Vesicles as a FGL1/PD‐L1 Dual‐Targeting Delivery System for Alleviating Immune Rejection (Adv. Sci. 3/2022)
Author(s) -
Tsai Hsiangi,
Wu Yingyi,
Liu Xiaoyan,
Xu Zhanxue,
Liu Longshan,
Wang Changxi,
Zhang Huanxi,
Huang Yisheng,
Wang Linglu,
Zhang Weixian,
Su Dandan,
Khan Fahim Ullah,
Zhu Xiaofeng,
Yang Rongya,
Pang Yuxin,
Eriksson John E.,
Zhu Haitao,
Wang Dongqing,
Jia Bo,
Cheng Fang,
Chen Hongbo
Publication year - 2022
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.202270020
Subject(s) - extracellular vesicles , microbiology and biotechnology , transplantation , immune system , mesenchymal stem cell , extracellular , vesicle , microvesicles , chemistry , cancer research , biology , immunology , medicine , biochemistry , membrane , microrna , gene
Small Extracellular Vesicles The simultaneous high expression of LAG‐3 and PD‐1 on T cells in cardiac transplantation mouse models and clinical renal transplantation patients provides the possibility to establish immune tolerance by giving their ligand molecules. In article number 2102634 by Bo Jia, Fang Cheng, Hongbo Chen, and co‐workers, small extracellular vesicles derived from bioengineered PD‐L1/FGL1‐expressed mesenchymal stem cells encapsulated with low‐dose FK506 exerted a powerful synergistic inhibitory effect on T cell activation and, therefore, prolonged grafts survival.